Technical Analysis for RCUS - Arcus Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 16.85 | -0.30% | -0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | -0.30% | |
| NR7 | Range Contraction | -0.30% | |
| Upper Bollinger Band Walk | Strength | -0.30% | |
| Bearish Engulfing | Bearish | -3.49% | |
| 200 DMA Support | Bullish | -3.49% | |
| New Uptrend | Bullish | -3.49% | |
| Upper Bollinger Band Walk | Strength | -3.49% | |
| Upper Bollinger Band Touch | Strength | -3.49% | |
| Crossed Above 200 DMA | Bullish | -3.99% | |
| Pocket Pivot | Bullish Swing Setup | -3.99% |
| Alert | Time |
|---|---|
| 50 DMA Support | 39 minutes ago |
| 10 DMA Support | 44 minutes ago |
| Down 1% | 44 minutes ago |
| Fell Below 50 DMA | about 1 hour ago |
| Fell Below Previous Day's Low | about 1 hour ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.47 |
| 52 Week Low | 12.96 |
| Average Volume | 643,901 |
| 200-Day Moving Average | 17.22 |
| 50-Day Moving Average | 16.74 |
| 20-Day Moving Average | 15.97 |
| 10-Day Moving Average | 16.59 |
| Average True Range | 0.93 |
| RSI (14) | 54.75 |
| ADX | 25.86 |
| +DI | 25.89 |
| -DI | 12.38 |
| Chandelier Exit (Long, 3 ATRs) | 15.27 |
| Chandelier Exit (Short, 3 ATRs) | 16.90 |
| Upper Bollinger Bands | 17.68 |
| Lower Bollinger Band | 14.25 |
| Percent B (%b) | 0.77 |
| BandWidth | 21.51 |
| MACD Line | 0.21 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.2564 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.86 | ||||
| Resistance 3 (R3) | 17.96 | 17.73 | 17.70 | ||
| Resistance 2 (R2) | 17.73 | 17.49 | 17.69 | 17.65 | |
| Resistance 1 (R1) | 17.32 | 17.34 | 17.21 | 17.22 | 17.59 |
| Pivot Point | 17.09 | 17.09 | 17.04 | 17.05 | 17.09 |
| Support 1 (S1) | 16.68 | 16.85 | 16.57 | 16.58 | 16.21 |
| Support 2 (S2) | 16.45 | 16.70 | 16.41 | 16.15 | |
| Support 3 (S3) | 16.04 | 16.45 | 16.10 | ||
| Support 4 (S4) | 15.94 |
